Role of Anti-TREK-1 Autoantibodies in SCVF (TRACK-VF)

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Status: Invitation-only

Conditions: Short-coupled Ventricular Fibrillation; Idiopathic Ventricular Fibrillation

Treatments: Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies; Genetic: DPP6 risk haplotype

Study type: Observational

Funder types: Other

Identifiers

NCT06943365

MP-10-2025-4338

Details and patient eligibility

About

Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.

Full description

Please refer to the uploaded study protocol

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• Diagnosis of SCVF as per current criteria
• Willingness to provide written informed consent

Exclusion criteria

• SCVF patients < age 18

Trial design

300 participants in 1 patient group

SCVF

Description:

Probands with diagnosis of SCVF

Treatment:

Genetic: DPP6 risk haplotype

Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies